1H-Pyrazolo[3,4-c]pyridine-3-carboxylic acid, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-, ethyl ester

Endpoint summary

Link to relevant study record(s)

Reference

Endpoint:

basic toxicokinetics, other

Remarks:

Theoretical assessment

Type of information:

other: Expert statement

Adequacy of study:

key study

Study period:

3 October 2019

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: see "Remark"

Remarks:

Theoretical assessment taking all currrently available relevant information into account, based on the REACH Guidance: Guidance on Information Requirements and Chemical Safety Assessment, Chapter R.7c Endpoint specific guidance. Since this is a theoretical assessment, the Klimisch value cannot be 1.

GLP compliance:

no

Type:

absorption

Results:

For risk assessment purposes the factors are set at 50% for oral absorption, inhalation absorption and dermal absorption.

Conclusions:

A toxicokinetic assessment was performed based on the available data. Based on the physical/chemical properties of the substance, absorption factors for this substance are derived to be 50% (oral), 50% (inhalation) and 50% (dermal) for risk assessment purposes. The bioaccumulation potential is expected to be low.

Description of key information

A toxicokinetic assessment was performed based on the available data. Based on the physical/chemical properties of the substance, absorption factors for this substance are derived to be 50% (oral), 50% (inhalation) and 50% (dermal) for risk assessment purposes. The bioaccumulation potential is expected to be low.

Key value for chemical safety assessment

Bioaccumulation potential:

low bioaccumulation potential

Absorption rate - oral (%):

50

Absorption rate - dermal (%):

50

Absorption rate - inhalation (%):

50